Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2258126rdf:typepubmed:Citationlld:pubmed
pubmed-article:2258126lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:2258126lifeskim:mentionsumls-concept:C0205246lld:lifeskim
pubmed-article:2258126lifeskim:mentionsumls-concept:C0205464lld:lifeskim
pubmed-article:2258126lifeskim:mentionsumls-concept:C0871161lld:lifeskim
pubmed-article:2258126lifeskim:mentionsumls-concept:C0104882lld:lifeskim
pubmed-article:2258126lifeskim:mentionsumls-concept:C0124755lld:lifeskim
pubmed-article:2258126pubmed:issue4lld:pubmed
pubmed-article:2258126pubmed:dateCreated1991-1-29lld:pubmed
pubmed-article:2258126pubmed:abstractTextAzuletil sodium (AZE, 100 mg/kg, p.o.) did not affect the general behaviors, spontaneous motor activity, pentobarbital-induced hypnosis and body temperature. Furthermore, it did not elicit anticonvulsant and muscle relaxant actions. However, AZE (300 mg/kg, p.o.) elicited a stiff gate and slightly inhibited the spontaneous motor activity and electroshock-induced convulsions. It had no influence on spontaneous EEG activities, even at 30 mg/kg, i.v. AZE inhibited acetic acid-induced writhing moderately at doses above 100 mg/kg. AZE at concentrations up to 10(-5) g/ml did not affect agonist-induced contractions of the isolated ileum, trachea, vas deference and uterus, but inhibited serotonin and oxytocin-induced contraction at concentrations above 3 x 10(-4) and 10(-5) g/ml, respectively; and it also depressed spontaneous movements of the ileum and uterus at concentrations above 3 x 10(-4) g/ml. AZE caused no changes in blood pressure (BP), heart rate (HR), left ventricular pressure, ECG, tracheal pressure (TP), femoral blood flow (FBF) and coronary blood flow (CBF) at doses up to 10 mg/kg, i.v. in anesthetized dogs, but it caused an increase or a decrease in BP, an increase in TP and an increase in CBF at 30 mg/kg, i.v. However, even at 300 mg/kg, p.o., it caused no changes in BP and HR in conscious rats. AZE moderately promoted the charcoal transport. AZE at doses up to 300 mg/kg, p.o. did not affect urine volume, urinary electrolyte excretion, blood glucose and prothrombin time. These results suggest that AZE at anti-ulcer doses of 10-100 mg/kg, p.o. does not have noticeable effects on general pharmacological properties, and there is no marked differences as compared with those of GAS.lld:pubmed
pubmed-article:2258126pubmed:languagejpnlld:pubmed
pubmed-article:2258126pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2258126pubmed:citationSubsetIMlld:pubmed
pubmed-article:2258126pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2258126pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2258126pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2258126pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2258126pubmed:statusMEDLINElld:pubmed
pubmed-article:2258126pubmed:monthOctlld:pubmed
pubmed-article:2258126pubmed:issn0015-5691lld:pubmed
pubmed-article:2258126pubmed:authorpubmed-author:MochizukiSSlld:pubmed
pubmed-article:2258126pubmed:authorpubmed-author:SekiguchiHHlld:pubmed
pubmed-article:2258126pubmed:authorpubmed-author:WakabayashiSSlld:pubmed
pubmed-article:2258126pubmed:authorpubmed-author:TomiyamaAAlld:pubmed
pubmed-article:2258126pubmed:authorpubmed-author:KashimaMMlld:pubmed
pubmed-article:2258126pubmed:authorpubmed-author:KosakaiKKlld:pubmed
pubmed-article:2258126pubmed:issnTypePrintlld:pubmed
pubmed-article:2258126pubmed:volume96lld:pubmed
pubmed-article:2258126pubmed:ownerNLMlld:pubmed
pubmed-article:2258126pubmed:authorsCompleteYlld:pubmed
pubmed-article:2258126pubmed:pagination185-204lld:pubmed
pubmed-article:2258126pubmed:dateRevised2011-7-27lld:pubmed
pubmed-article:2258126pubmed:meshHeadingpubmed-meshheading:2258126-...lld:pubmed
pubmed-article:2258126pubmed:meshHeadingpubmed-meshheading:2258126-...lld:pubmed
pubmed-article:2258126pubmed:meshHeadingpubmed-meshheading:2258126-...lld:pubmed
pubmed-article:2258126pubmed:meshHeadingpubmed-meshheading:2258126-...lld:pubmed
pubmed-article:2258126pubmed:meshHeadingpubmed-meshheading:2258126-...lld:pubmed
pubmed-article:2258126pubmed:meshHeadingpubmed-meshheading:2258126-...lld:pubmed
pubmed-article:2258126pubmed:meshHeadingpubmed-meshheading:2258126-...lld:pubmed
pubmed-article:2258126pubmed:meshHeadingpubmed-meshheading:2258126-...lld:pubmed
pubmed-article:2258126pubmed:meshHeadingpubmed-meshheading:2258126-...lld:pubmed
pubmed-article:2258126pubmed:meshHeadingpubmed-meshheading:2258126-...lld:pubmed
pubmed-article:2258126pubmed:meshHeadingpubmed-meshheading:2258126-...lld:pubmed
pubmed-article:2258126pubmed:meshHeadingpubmed-meshheading:2258126-...lld:pubmed
pubmed-article:2258126pubmed:meshHeadingpubmed-meshheading:2258126-...lld:pubmed
pubmed-article:2258126pubmed:meshHeadingpubmed-meshheading:2258126-...lld:pubmed
pubmed-article:2258126pubmed:meshHeadingpubmed-meshheading:2258126-...lld:pubmed
pubmed-article:2258126pubmed:meshHeadingpubmed-meshheading:2258126-...lld:pubmed
pubmed-article:2258126pubmed:meshHeadingpubmed-meshheading:2258126-...lld:pubmed
pubmed-article:2258126pubmed:year1990lld:pubmed
pubmed-article:2258126pubmed:articleTitle[General pharmacological properties of an anti-ulcer drug, azuletil sodium (KT1-32)].lld:pubmed
pubmed-article:2258126pubmed:affiliationResearch Laboratories, Kotobuki Seiyaku Co., Ltd., Nagano, Japan.lld:pubmed
pubmed-article:2258126pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2258126pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:2258126pubmed:publicationTypeEnglish Abstractlld:pubmed